Results 71 to 80 of about 34,307 (290)

Current Peptide HIV Type-1 Fusion Inhibitors

Antiviral Chemistry and Chemotherapy, 2009
There are now 26 antiretroviral drugs and 6 fixed-dose combinations, including reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors and fusion (or entry) inhibitors, approved by the US Food and Drug Administration for clinical use.
Wei, Pang, Siu-Cheung, Tam, Yong-Tang, Zheng   +2 more
openaire   +2 more sources

Update on the development of HIV entry inhibitors

, 2008
HIV fusion and entry are two steps in the viral lifecycle that can be targeted by several classes of antiviral drugs. The discovery of chemokines focused the attention on cellular co-receptors used by the virus for entering cells, and on the various ...
Rusconi S., Supuran C. T., Mastrolorenzo A., Maresca A.   +3 more
core   +1 more source

ZNF33B Promotes Japanese Encephalitis Virus Infection by Regulating the Stability of M6A‐Modified Trim25 to Control the Autophagy Process

Advanced Science, EarlyView.
Upon JEV infection, ZNF33B recruits METTL14 to stabilize the METTL3‐METTL14 m6A methyltransferase complex, leading to increased m6A modification of host transcripts, including Trim25 mRNA. ZNF33B selectively binds m6A‐modified sites on Trim25 mRNA and accelerates its decay, resulting in reduced TRIM25 protein abundance.
Jian Du, Chunwei Li, Jiyuan Luo, Huizhi Zhang, Jinyan Zhang, Suya Wang, Huanchun Chen, Hongli Xu, Xiangmin Li, Ping Qian   +9 more
wiley   +1 more source

Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors. [PDF]

PLoS ONE, 2011
The B', CRF07_BC and CRF01_AE are the predominant HIV-1 subtypes in China. It is essential to determine their baseline susceptibility to HIV entry inhibitors before these drugs are used in China.The baseline susceptibility of 14 representative HIV-1 ...
Xiaoling Yu, Lin Yuan, Yang Huang, Weisi Xu, Zhiming Fang, Shuwen Liu, Yiming Shao, Shibo Jiang, Liying Ma   +8 more
doaj   +1 more source

Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor [PDF]

Journal of Biological Chemistry, 2008
Enfuvirtide (T20) is the first and only HIV-1 fusion inhibitor approved for clinical use, but it can easily induce drug resistance limiting its practical application. A novel anti-HIV peptide, termed sifuvirtide, was designed based on the three-dimensional structure of the HIV-1 gp41 fusogenic core conformation.
Yuxian, He, Yonghong, Xiao, Haifeng, Song, Qing, Liang, Dan, Ju, Xin, Chen, Hong, Lu, Weiguo, Jing, Shibo, Jiang, Linqi, Zhang   +9 more
openaire   +2 more sources

An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli

, 2006
Objectives: To engineer Lactobacillus spp. to secrete HIV-1 fusion inhibitors with potent neutralizing activity against primary HIV-1 isolates. Methods: HIV-1 fusion inhibitors (FI-1, FI-2, and FI-3) were introduced into the previously developed shuttle ...
Pusch, O., Wells, J., Rmanratnam, B., Kalyanaraman, R., Wells, J.M., Ramratnam, B., Boden, D., Tucker, L.D.   +7 more
core   +1 more source

RNA‐Binding Protein RBM25 Targets the mRNA Stability of GTPase Rab22a to Restrict Viral Entry and Infection

Advanced Science, EarlyView.
This study identifies RNA‐binding protein RBM25 as a broad‐spectrum antiviral factor acting independently of type I interferon. It blocks viral entry by suppressing GTPase Rab22a via the RC3H1‐mediated destabilization of Rab22a mRNA. Viral downregulation of RBM25 enhances GTPase Rab22a expression and viral entry, revealing an unreported post ...
Yingying Ding, Huiying Chen, Yuyu Jiang, Chunyan Zhao, Jie Bai, Yan Xiang, Zeting Wang, Xixi Wang, Bing Rui, Wanda Tang, Yue Ding, Zhenzhen Zhan, Yunkai Zhang, Xingguang Liu   +13 more
wiley   +1 more source

Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1

Virology Journal, 2008
We describe a novel strategy in which two inhibitors of HIV viral entry were incorporated into a single molecule. This bifunctional fusion inhibitor consists of an antibody blocking the binding of HIV to its co-receptor CCR5, and a covalently linked ...
Cammack Nick, Fischer Stephan, Zhang Jun, Rao Eileen, Ji Changhua, Jekle Andreas, Kopetzki Erhard, Sankuratri Surya, Heilek Gabrielle   +8 more
doaj   +1 more source

Complementary approaches to target human respiratory syncytial virus using small molecule ligands [PDF]

, 2012
In the current project, situated at the interface of chemistry and virology, complementary drug discovery approaches (high-throughput screening and structurebased drug design) have been exploited in order to discover novel small molecule inhibitors of ...
Lardeau, Charles-Hugues Claude Jean
core  

Recent advances in the construction of humanized animal models and applications in translational medicine

Animal Models and Experimental Medicine, EarlyView.
Substantial advances have been achieved in the development of humanized mouse models, which have proven highly valuable in evaluating cancer immunotherapies and elucidating the mechanisms of infectious diseases. There is now a growing shift in research toward larger animal models—such as pigs—that offer greater physiological similarity to humans ...
Yanan Lyu, Yong‐Guang Yang, Zheng Hu
wiley   +1 more source